PHGE Share Price | BiomX, Inc. Stock Analysis & Recommendation

Q: What does BiomX, Inc. do?

Overview: BiomX, Inc. is a microbiome company focused on developing natural and engineered phage therapies within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Net Profit: -8 Million (Quarterly Results - Mar 2025) Market Cap: USD 10.21 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.81 Return on Equity: -177.29% Price to Book: 0.42Contact Details: Address: 7 Pinhas Sapir St, Floor 2, NESS-ZIONA NY: 7414002 Tel: 1 646 4659000

Q: Is BiomX, Inc. technically bullish or bearish?

As of 27 August 2025, the technical trend for BiomX, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a mildly bearish position and the weekly RSI showing bearish momentum. While the MACD is mildly bullish on both weekly and monthly time frames, the overall indicators suggest weakness. Additionally, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -30.31% versus the S&P 500's 12.22%, and a one-year return of -50.41% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.28 k

Shareholding (Sep 2025)

FII

0.23%

Held by 4 FIIs

DII

82.84%

Held by 2 DIIs

Promoter

16.91%

How big is BiomX, Inc.?

22-Jun-2025

As of Jun 18, BiomX, Inc. has a market capitalization of 10.21 million, with net sales of 0.00 million and a net profit of -16.15 million over the latest four quarters. Shareholder's funds are at 24.15 million, and total assets amount to 98.81 million.

View full answer

What does BiomX, Inc. do?

22-Jun-2025

BiomX, Inc. is a microbiome company specializing in natural and engineered phage therapies in the Pharmaceuticals & Biotechnology sector. As of March 2025, it has a market cap of $10.21 million and reported a net profit loss of $8 million.

View full answer

Who are in the management team of BiomX, Inc.?

22-Jun-2025

As of March 2022, the management team of BiomX, Inc. includes Dr. Russell Greig (Independent Chairman), Mr. Jonathan Solomon (CEO), and several independent directors: Dr. Gbola Amusa, Mr. Jonas Grossman, Dr. Alan Moses, Mr. Paul Sekhri, and Ms. Lynne Sullivan. They are responsible for the company's strategic direction.

View full answer

Is BiomX, Inc. technically bullish or bearish?

20-Sep-2025

As of August 27, 2025, BiomX, Inc. is in a mildly bearish trend, with daily moving averages and weekly RSI indicating weakness, despite a mildly bullish MACD, and it has significantly underperformed the S&P 500 with year-to-date and one-year returns of -30.31% and -50.41%, respectively.

View full answer

Compare BiomX, Inc. with Similar Stocks

AquaBounty Technologies, Inc.Elutia, Inc.Orgenesis, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.63

Return on Equity

-322.48%

Price to Book

0.45

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

801.19%

6 Months

723.86%

1 Year

51.19%

2 Years

49.06%

3 Years

-20.09%

4 Years

-91.21%

5 Years

-90.55%

BiomX, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-7.19%

EBIT to Interest (avg)

-16.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.81

Sales to Capital Employed (avg)

Tax Ratio

0.07%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

58.19%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.50

EV to EBIT

0.20

EV to EBITDA

0.21

EV to Capital Employed

-1.67

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-177.29%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 1 Schemes (0.02%)

Foreign Institutions

Held by 4 Foreign Institutions (0.23%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -700.00% vs 115.62% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.10",
          "val2": "-9.40",
          "chgp": "24.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.50",
          "val2": "11.90",
          "chgp": "-87.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.00",
          "val2": "1.00",
          "chgp": "-700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.44% vs 7.42% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-37.20",
          "val2": "-26.80",
          "chgp": "-38.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.80",
          "val2": "2.50",
          "chgp": "12.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "18.30",
          "val2": "0.10",
          "chgp": "18,200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.70",
          "val2": "-26.20",
          "chgp": "32.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.10

-9.40

24.47%

Interest

0.00

Exceptional Items

1.50

11.90

-87.39%

Consolidate Net Profit

-6.00

1.00

-700.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -700.00% vs 115.62% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-37.20

-26.80

-38.81%

Interest

2.80

2.50

12.00%

Exceptional Items

18.30

0.10

18,200.00%

Consolidate Net Profit

-17.70

-26.20

32.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 32.44% vs 7.42% in Dec 2023

All Annual Results

Company CV

About BiomX, Inc.

BiomX, Inc.

Pharmaceuticals & Biotechnology

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Company Coordinates

Company Details

7 Pinhas Sapir St , Floor 2 , NESS-ZIONA NY : 7414002

Tel: 1 646 4659000

Registrar Details

BiomX, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is BiomX, Inc.?

Watch in Real-Time

What does BiomX, Inc. do?

Who are in the management team of BiomX, Inc.?

Is BiomX, Inc. technically bullish or bearish?

Compare BiomX, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About BiomX, Inc.

Company Coordinates